- Home
- FSHP vs MDXH Comparison
FSHP vs MDXH Comparison
Compare FSHP & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- MDXH
- Stock Information
- Founded
- FSHP 2018
- MDXH 2003
- Country
- FSHP United States
- MDXH Belgium
- Employees
- FSHP N/A
- MDXH N/A
- Industry
- FSHP
- MDXH
- Sector
- FSHP
- MDXH
- Exchange
- FSHP NYSE
- MDXH Nasdaq
- Market Cap
- FSHP 92.2M
- MDXH 84.6M
- IPO Year
- FSHP 2024
- MDXH 2021
- Fundamental
- Price
- FSHP $10.48
- MDXH $2.09
- Analyst Decision
- FSHP
- MDXH Buy
- Analyst Count
- FSHP 0
- MDXH 1
- Target Price
- FSHP N/A
- MDXH $6.00
- AVG Volume (30 Days)
- FSHP 4.3K
- MDXH 75.5K
- Earning Date
- FSHP 01-01-0001
- MDXH 05-14-2025
- Dividend Yield
- FSHP N/A
- MDXH N/A
- EPS Growth
- FSHP N/A
- MDXH N/A
- EPS
- FSHP 0.20
- MDXH N/A
- Revenue
- FSHP N/A
- MDXH $94,507,000.00
- Revenue This Year
- FSHP N/A
- MDXH $23.38
- Revenue Next Year
- FSHP N/A
- MDXH $16.84
- P/E Ratio
- FSHP $52.52
- MDXH N/A
- Revenue Growth
- FSHP N/A
- MDXH 25.46
- 52 Week Low
- FSHP $9.99
- MDXH $1.35
- 52 Week High
- FSHP $10.48
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- MDXH 74.52
- Support Level
- FSHP N/A
- MDXH $1.67
- Resistance Level
- FSHP N/A
- MDXH $1.99
- Average True Range (ATR)
- FSHP 0.00
- MDXH 0.13
- MACD
- FSHP 0.00
- MDXH 0.02
- Stochastic Oscillator
- FSHP 0.00
- MDXH 97.67
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.